The Company has a Scientific Advisory Board made up of world class scientists
and researchers who are leaders in their fields. The Scientific Advisory Board
provides input and advice to the Company's Board of Directors.
Ray C. Williams, D.M.D.
Chairman, Scientific Advisory Board
Dr. Williams is one of the founders of Orapharma, Inc. which successfully completed a $76 million IPO in 2000 and was subsequently purchased by Johnson & Johnson for approximately $85 million, net of cash, in 2003. Dr. Williams is Straumann Distinguished Professor and Chairman of the Department of Periodontology at the University of North Carolina School of Dentistry at Chapel Hill. He received his DMD (with honors) from the University of Alabama School of Dentistry and his certificate in Periodontology and Oral Medicine from the Harvard School of Dental Medicine. He was also a Postdoctoral Fellow in Microbiology at Forsyth Dental Center. >From 1974 to 1994 Dr. Williams was a member of the faculty of the Harvard School of Dental Medicine where from 1981 to 1994 he was Graduate Program Director and from 1983 to 1994 he was Head of the Department of Periodontology. Dr. Williams was also Associate Dean for Postdoctoral Education from 1989-1994. In 1994 he was appointed Professor and Chair of the Department of Periodontology at UNC-Chapel Hill. His major research interests include: pharmacologic interception of the progression of periodontal disease, the risk for periodontitis, periodontitis as a risk for systemic conditions and wound healing around teeth and around dental implants. Dr. Williams has authored over 200 papers and abstracts on his work. He lectures nationally and internationally each year. As an educator, Dr. Williams has trained over 120 women and men in the specialty of Periodontics who have gone on to assume positions of leadership in private practice, academia and industry. In 2004, he received the American Academy of Periodontology’s Outstanding Educator Award.
Ann Progulske-Fox, Ph.D.
Scientific Advisory Board Member
Dr. Progulske-Fox is a Professor at the University of Florida College of Dentistry
and the Director of the University's Center for Molecular Microbiology. Dr. Fox
is a co-founder of iviGene and a co-inventor of IVIAT and of the A.a. and P.g.
technolgoy. Dr. Progulske-Fox is a leading researcher in oral infectious diseases,
a member of the International Board of Editors of the scientific journals FEMS
Microbiology Letters, Methods in Cell Science, and Oral Diseases. She is active
in numeroul scientific associations and has published many scientific papers on
the moleicular biology of microbial diseases. She received her B.S. from South
Dakota State University and her Ph.D. in Microbiology from the University of Massachusetts.
Martin Handfield, M.Sc. and Ph.D.
Scientific Advisory Board Member
Dr. Handfield is an Assistant Professor at the Universtiy of Florida College
of Dentistry. He is a co-inventor of IVIAT and the A.a. and P.g. technology and
a co-founder of iviGene Corporation. Dr. Handfield serves on the iviGene Scientific
Advisory Board and is a Director of EpiCure Solutions Corporation (Florida). He
is a distinguished young researcher with a number of honors and awards, including
a Ph.D. Scholar Award from the Canadian Cystic Fibrosis Foundation. He has published
several scientific papers and reviews and his laboratory is currently funded by
three National Institutes of Health Grants. Dr. Handfield received his B.Sc. (Biochemistry),
M.Sc. (Microbiology) and Ph.D. (Molecular Pathogenesis) at Laval University (Canada).
Dr. Michael Clare-Salzler, MD
Scientific Advisory Board Member
Dr. Clare-Salzler is the inventor of the COX-2 technology, and has been an Associate
Professor with the University of Florida College of Medicine Department of Pathology
since 1997. His research focus has been on the cellular, molecular, and genetic
basis for the immunopathogenisis of juvenile or type-1 diabetes and other autoimmune
endocrine diseases. His recnet work has led to a number of advances in the identification
of immunophenotypes in subjects with a high risk for type-1 diabetes. He received
his B.S. from Notre Dame and his M.D. from SUNY at Buffalo School of Medicine
(1979). He was a Research Fellow in Endocrinology at the University of Calilfornia
Los Angeles from 1985 to 1988, and is board certified by the American Board of
Internal Medicine in Endocrinology. He has been on staf at U.F. since 1993.
